Dapagliflozin is a selective and reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2), which works independently of insulin.
The safety and efficacy of Farxiga were evaluated in 16 clinical trials that involved more than 9,400 patients with type 2 diabetes. Study results showed improvement in HbA1c after treatment with Farxiga.
Farxiga has been studied as monotherapy and in combination with other type 2 diabetes treatment including, metformin, pioglitazone, glimepiride, sitagliptin, and insulin.
The FDA has required six post-marketing studies for Farxiga:
- A cardiovascular outcomes trial (CVOT) to evaluate the cardiovascular risk of Farxiga in patients with high baseline risk of cardiovascular disease
- A double-blind, randomized, controlled assessment of bladder cancer risk in patients enrolled in the CVOT
- An animal study evaluating the role of Farxiga-induced urinary flow/rate and composition changes on bladder tumor promotion in rodents
- Two clinical trials to assess the pharmacokinetics, efficacy, and safety in pediatric patients
- An enhanced pharmacovigilance program to monitor reports of liver abnormalities and pregnancy outcomes